Intervención farmacéutica en el manejo de inhaladores con pacientes EPOC citados para una espirometría en un centro de salud

  1. Cristina Peral Bolaños 1
  2. Luis Baró Rodriguez 2
  3. Rosa Carabaño Moral 3
  4. Maria V. Martín-Ruiz
  5. Esperanza Sanz Sanmartin 4
  6. Aranzazu Garcia Buendia 3
  7. Maria Dolores Llamas Del Castillo 2
  8. Fernando Martinez Martinez 5
  9. Rocio Martin Valero 6
  10. Isabel M. Molina-Conejo 4
  1. 1 Primary care pharmacist, Health care Federica Montseny, Madrid. Doctoral student at the university of Granada
  2. 2 Primary care pharmacist, Costa del Sol Health Care Area, Malaga, Spain
  3. 3 Specialist in family medicine, Health care Arroyo de la Miel, Costa del Sol Health Care Area, Malaga, Spain.
  4. 4 Qualified nurse, Health care Arroyo de la Miel, Costa del Sol Health Care Area, Malaga, Spain.
  5. 5 University of Granada, Faculty of Pharmacy, Cathedratic Department of Pharmaceutical Care, Spain
  6. 6 University of Málaga, Faculty of Health Sciencies, Professor Department of Physiotherapy, Spain
Show affiliations +
Journal:
Pharmaceutical care España

ISSN: 1139-6202

Year of publication: 2023

Volume: 25

Issue: 2

Pages: 34-49

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Pharmaceutical care España

Abstract

Background: the usage of inhalers is something complex. This work with COPD patients pretends that, after the pharmacist intervention, the correct usage of these drugs is guaranteed so as to im-prove the quality of life. Methods: the nurse set a date to do an spirometry to the patients. On the other hand, the pharmacist assessed the usage of the inhalers and carried out the adherence and quality of life tests. Three months after, the patients came back to the con-sultation and the pharmacist repeated the same procedure to detect any possible change after the intervention.Results: on those patients that attended both ap-pointments, it was seen that there were statistically significant changes between the adherence punc-tuation regarding both appointments. The average of punctuation is higher in the second appointment (49.09) in respect to the first one (46.45), this is a significant difference with a p<0.05. The quality of life was the same in both appointments and the errors average in the usage of inhalators in the second appointment decreased (1773) significantly in respect to the errors average in the first appoint-ment (4727).Conclusion: the intervention of a pharmacist in a multidisciplinary team to the following of COPD pa-tients is advantageous to these patients, mainly in relation to the usage of inhalers and the adherence to treatment.

Bibliographic References

  • World Health Organization. The top 10 causes of death [Internet]. 2020 [cited 2021 Jun 16]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
  • Sobradillo V, et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch. Bronconeumol. 1999; 35(4):159–166, 1999. DOI: 10.1016/S0300-2896(15)30272-6
  • Miravitlles M, et al. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch. Bronconeumol. 2022; 58(1):69–81. DOI: 10.1016/j.arbres.2021.03.005
  • M. D. E. Sanidad and S. S. E. Igualdad, “Plan de calidad para el Sistema Nacional de Salud 2010,” Plan Calid. para el Sist. Nac. Salud, 2010. Completar referencia (fecha de acceso y disponible en)
  • Miravitlles M, et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009; 64(10):863–868, 2009. DOI: 10.1136/thx.2009.115725
  • Global Initiative for Chronic Obstructive Lung Disease. 2021 Global Strategy for Prevention. Diagnosis and Management of COPD. GOLD; 2021. Disponible en: www.goldcopd.org
  • Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. J. Asthma. 2010; 47():162–165. , 2010.
  • Tommelein E, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): A randomized controlled trial. Br. J. Clin. Pharmacol. 2014; 77(5):756–766. https://doi.org/10.1111/bcp.12242
  • Vogelmeier C, López V, Frith P, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (2018 Report). Global Initiative for Chronic Obstructive Lung Disease GOLD 2018. Disponible en: www.goldcopd.org
  • Plaza V, López-Viña A, Cosio BG. El test de adhesión a los inhaladores. Arch Bronconeumol. 2017; 53(7):360-1. DOI: 10.1016/j.arbres.2016.08.006
  • Jimenez-Ruiz CA, Pascual Lledó JF, Cícero Guerrero A, Cristóbal Fernández M, et al. Análisis de la calidad de vida en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) que dejan de fumar. Med. Fam. Semer. 2018; 44(5):310–315. https://doi.org/10.1016/j.semerg.2017.08.003
  • Palo Serrano J. Uso de inhaladores: detección de errores e intervención por el farmacéutico comunitario. Farmacéuticos Comunitarios. 2016; 8(4):18-25. doi: 10.5672/FC.2173-9218.(2016/Vol8).004.03
  • Gorgas Torner MQ, et al. Programa de atención farmacéutica integrada en pacientes con enfermedades crónicas. Farm. Hosp. 2012; 36(4):229–239. , 2012. https://doi.org/10.1016/j.farma.2011.06.015
  • Davis E, Marra C, Gamble JM, Farrell J, Lockyer J, FitzGerald JM, et al. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): Study protocol for a randomized controlled trial. Trials [Internet]. 2016;17(1):1–8. Disponible en: http://dx.doi.org/10.1186/s13063-016-1623-7
  • F. Carrión Valero, S. Paulos Dos Santos, and B. R. Celli. Tabaquismo en pacientes con EPOC, ¿un nuevo fenotipo clínico?. Arch. Bronconeumol. 2018; 54(5):249–250. DOI: 10.1016/j.arbres.2017.10.021
Data source: Dialnet